BEAM
Price
$28.81
Change
+$0.11 (+0.38%)
Updated
Dec 24, 02:00 PM (EDT)
70 days until earnings call
DAWN
Price
$12.67
Change
-$0.02 (-0.16%)
Updated
Dec 24, 02:00 PM (EDT)
76 days until earnings call
Ad is loading...

BEAM vs DAWN

Header iconBEAM vs DAWN Comparison
Open Charts BEAM vs DAWNBanner chart's image
Beam Therapeutics
Price$28.81
Change+$0.11 (+0.38%)
Volume$39.91K
CapitalizationN/A
Day One Biopharmaceuticals
Price$12.67
Change-$0.02 (-0.16%)
Volume$26.8K
CapitalizationN/A
BEAM vs DAWN Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DAWN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. DAWN commentary
Dec 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and DAWN is a Hold.

Ad is loading...
COMPARISON
Comparison
Dec 25, 2024
Stock price -- (BEAM: $28.70 vs. DAWN: $12.69)
Brand notoriety: BEAM and DAWN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 57% vs. DAWN: 62%
Market capitalization -- BEAM: $2.39B vs. DAWN: $1.28B
BEAM [@Biotechnology] is valued at $2.39B. DAWN’s [@Biotechnology] market capitalization is $1.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileDAWN’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • DAWN’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than DAWN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while DAWN’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 4 bearish.
  • DAWN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DAWN is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -0.80% price change this week, while DAWN (@Biotechnology) price change was +0.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.99%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +3.17%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

DAWN is expected to report earnings on Mar 10, 2025.

Industries' Descriptions

@Biotechnology (-0.99% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.39B) has a higher market cap than DAWN($1.28B). BEAM YTD gains are higher at: 5.437 vs. DAWN (-13.082). BEAM has higher annual earnings (EBITDA): -160.83M vs. DAWN (-210.08M). BEAM has more cash in the bank: 926M vs. DAWN (558M). DAWN has less debt than BEAM: DAWN (2.62M) vs BEAM (162M). BEAM has higher revenues than DAWN: BEAM (350M) vs DAWN (102M).
BEAMDAWNBEAM / DAWN
Capitalization2.39B1.28B187%
EBITDA-160.83M-210.08M77%
Gain YTD5.437-13.082-42%
P/E RatioN/AN/A-
Revenue350M102M343%
Total Cash926M558M166%
Total Debt162M2.62M6,195%
TECHNICAL ANALYSIS
Technical Analysis
BEAMDAWN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 26 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DAWN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NVLIX61.960.44
+0.72%
Nuveen Winslow Large-Cap Growth ESG I
VFWSX113.600.79
+0.70%
Vanguard FTSE All-Wld ex-US Idx Instl
SEVAX40.84N/A
N/A
NAA SMid Cap Value A
SBHCX12.58-0.01
-0.08%
Segall Bryant & Hamill Small Cap Cre Ret
PSCZX25.03-0.03
-0.12%
PGIM Jennison Small Company Z